Corcept Therapeutics CORT Tax on Share Settlement
Tax on Share Settlement at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's tax on share settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's tax on share settlement?
- Corcept Therapeutics (CORT) reported tax on share settlement of $5.76M in Q1 2026.
- How has Corcept Therapeutics's tax on share settlement changed year-over-year?
- Corcept Therapeutics's tax on share settlement decreased by 63.6% year-over-year, from $15.83M to $5.76M.
- What is the long-term trend for Corcept Therapeutics's tax on share settlement?
- Over 4 years (2021 to 2025), Corcept Therapeutics's tax on share settlement has grown at a 33.7% compound annual growth rate (CAGR), from $22.86M to $72.94M.
- What does tax on share settlement mean?
- Cash paid by the company to cover tax obligations arising from employee stock award vesting.
- How do you interpret tax on share settlement?
- An increase often correlates with higher levels of employee equity compensation or a higher stock price at the time of vesting.
- How does tax on share settlement compare across companies?
- Standard practice for companies utilizing equity-based compensation; peers report this as a financing cash outflow.